Glucocorticoid receptor – Histamine H1 receptor (GR/H1R)

The Glucocorticoid receptor (GR) and Histamine H1 receptor (H1R) represent a critical dual therapeutic target system, primarily utilized in the treatment of allergic and inflammatory conditions such as allergic rhinitis and asthma [1, 4]. The GR is a nuclear receptor that functions as a ligand-dependent transcription factor, mediating the potent anti-inflammatory effects of corticosteroids by regulating gene expression [5, 9]. In contrast, the H1R is a G protein-coupled receptor that mediates the acute physiological responses to histamine, including vasodilation, increased vascular permeability, and bronchoconstriction [8, 12]. Modern pharmacology has identified a significant molecular crosstalk between these two receptors, where H1R signaling pathways—specifically involving G-protein subunits and JNK-mediated phosphorylation—can enhance or inhibit GR-mediated transcriptional activity [2, 7]. This functional synergy is the rationale behind fixed-dose combination therapies, such as intranasal fluticasone/azelastine and mometasone/olopatadine, which provide more effective symptom relief than either agent alone [6]. By co-targeting these receptors, clinicians can achieve rapid control of allergic symptoms while simultaneously suppressing long-term inflammation, often allowing for a reduction in the required glucocorticoid dose and its associated systemic side effects [1, 5].

Other names

NR3C1HRH1Glucocorticoid receptor and Histamine H1 receptorGR-H1R crosstalkGCCRH1-R

Synergistic anti-inflammatory action achieved through the activation of the Glucocorticoid receptor and the antagonism or inverse agonism of the Histamine H1 receptor, involving molecular crosstalk that potentiates GR-mediated gene regulation [2, 5].